AIM: We investigated whether indoxyl sulfate (IS), a protein-bound uremic toxin, predicts prognosis after acute coronary syndrome (ACS). METHODS: Serum IS level was determined prospectively in 98 patients who underwent successful primary percutaneous coronary intervention for ACS. Patients on hemodialysis were excluded. The endpoint of this study was six-month composite events including death, nonfatal myocardial infarction, heart failure requiring hospitalization, and adverse bleeding events. RESULTS: During the mean follow-up period of 168 days, composite events occurred in 13.3% of cases. Serum IS level was significantly higher in subjects who developed composite events than in those without events (0.14±0.11 mg/dl vs. 0.06±0.04 mg/dl; p＜0.001). After adjusting for confounding factors, a Cox proportional hazard analysis revealed that the IS level (hazard ratio (HR): 10.6; 95% confidence interval (CI): 1.63-69.3, p=0.01), hemoglobin level (HR: 0.61; 95% CI: 0.43-0.87; p＜0.01), and left ventricular ejection fraction (LVEF) (HR: 0.95; 95% CI: 0.91-0.99; p=0.03) were independent predictive factors of composite events. Furthermore, IS level significantly conferred additional value to the combined established risks of LVEF and hemoglobin level for predicting the incidence of composite events (area under the curve: 0.82 vs. 0.88, p=0.01; net reclassification improvement: 0.67, p=0.01; and integrated discrimination improvement: 0.15, p＜0.01). CONCLUSIONS: The assessment of serum IS level has prognostic utility for the management of ACS.
AIM: We investigated whether indoxyl sulfate (IS), a protein-bound uremic toxin, predicts prognosis after acute coronary syndrome (ACS). METHODS: Serum IS level was determined prospectively in 98 patients who underwent successful primary percutaneous coronary intervention for ACS. Patients on hemodialysis were excluded. The endpoint of this study was six-month composite events including death, nonfatal myocardial infarction, heart failure requiring hospitalization, and adverse bleeding events. RESULTS: During the mean follow-up period of 168 days, composite events occurred in 13.3% of cases. Serum IS level was significantly higher in subjects who developed composite events than in those without events (0.14±0.11 mg/dl vs. 0.06±0.04 mg/dl; p＜0.001). After adjusting for confounding factors, a Cox proportional hazard analysis revealed that the IS level (hazard ratio (HR): 10.6; 95% confidence interval (CI): 1.63-69.3, p=0.01), hemoglobin level (HR: 0.61; 95% CI: 0.43-0.87; p＜0.01), and left ventricular ejection fraction (LVEF) (HR: 0.95; 95% CI: 0.91-0.99; p=0.03) were independent predictive factors of composite events. Furthermore, IS level significantly conferred additional value to the combined established risks of LVEF and hemoglobin level for predicting the incidence of composite events (area under the curve: 0.82 vs. 0.88, p=0.01; net reclassification improvement: 0.67, p=0.01; and integrated discrimination improvement: 0.15, p＜0.01). CONCLUSIONS: The assessment of serum IS level has prognostic utility for the management of ACS.
Authors: Harlan M Krumholz; Jeffrey L Anderson; Neil H Brooks; Francis M Fesmire; Costas T Lambrew; Mary Beth Landrum; W Douglas Weaver; John Whyte; Robert O Bonow; Susan J Bennett; Gregory Burke; Kim A Eagle; Jane Linderbaum; Frederick A Masoudi; Sharon-Lise T Normand; Ileana L Piña; Martha J Radford; John S Rumsfeld; James L Ritchie; John A Spertus Journal: Circulation Date: 2006-01-03 Impact factor: 29.690
Authors: Sylvestre Maréchaux; Annaïk Bellouin; Anne Sophie Polge; Marjorie Richardson-Lobbedez; Rémi Lubret; Philippe Asseman; Alain Berrebi; Christophe Chauvel; Jean Louis Vanoverschelde; Rémi Nevière; Brigitte Jude; Ghislaine Deklunder; Thierry H Le Jemtel; Pierre Vladimir Ennezat Journal: Arch Cardiovasc Dis Date: 2008-06-26 Impact factor: 2.340
Authors: E Magnus Ohman; Deepak L Bhatt; P Gabriel Steg; Shinya Goto; Alan T Hirsch; Chiau-Suong Liau; Jean-Louis Mas; Alain-Jean Richard; Joachim Röther; Peter W F Wilson Journal: Am Heart J Date: 2006-04 Impact factor: 4.749
Authors: Nisha I Parikh; Philimon Gona; Martin G Larson; Caroline S Fox; Emelia J Benjamin; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Daniel Levy Journal: Circulation Date: 2009-02-23 Impact factor: 29.690
Authors: Christopher B Granger; Robert J Goldberg; Omar Dabbous; Karen S Pieper; Kim A Eagle; Christopher P Cannon; Frans Van De Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Keith A A Fox Journal: Arch Intern Med Date: 2003-10-27
Authors: Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson Journal: Circulation Date: 2003-10-28 Impact factor: 29.690